girl

Thousand Oaks, CA, November 10, 2016 – Akriveia Therapeutics, an emerging immuno-oncology focused biotechnology company, today announced recent key additions to its research leadership team. Dr. C. Glenn Begley has joined the company as Chief Scientific Officer and Dr. Margaret Karow has joined as Vice President of Discovery and Preclinical Development.

--- read more ---

Thousand Oaks, CA, October 12, 2016 – Akriveia Therapeutics LLC, an emerging immuno-oncology focused biotechnology company, today announced its recent $7.5 million Series A investment by F-Prime Capital Partners. Thomas Beck and Ben Auspitz of F-Prime Capital Partners will join Akriveia’s Board of Directors alongside Akriveia’s Chief Executive Officer, Simon Tomlinson, with Dr. Beck becoming Chairman of the Board.

--- read more ---

Copyright © 2016 Akriveia Therapeutics / All rights reserved.